These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21394298)

  • 21. Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis.
    Vardakas KZ; Mavroudis AD; Georgiou M; Falagas ME
    Int J Antimicrob Agents; 2018 Apr; 51(4):535-547. PubMed ID: 29288723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of clinical manifestations and risk factors of mortality in Acinetobacter baumannii bloodstream infection].
    Zhang Y; Zhou H; Cai H; Yang Q; Shen Q; Shen Y; Zhou J
    Zhonghua Nei Ke Za Zhi; 2016 Feb; 55(2):121-6. PubMed ID: 26875581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Community-acquired bloodstream infections caused by Acinetobacter baumannii: A matched case-control study.
    Chen CT; Wang YC; Kuo SC; Shih FH; Chen TL; How CK; Yang YS; Lee YT
    J Microbiol Immunol Infect; 2018 Oct; 51(5):629-635. PubMed ID: 28701266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidrug Resistance Acinetobacter Bacteremia Secondary to Ventilator-Associated Pneumonia: Risk Factors and Outcome.
    Brotfain E; Borer A; Koyfman L; Saidel-Odes L; Frenkel A; Gruenbaum SE; Rosenzweig V; Zlotnik A; Klein M
    J Intensive Care Med; 2017 Oct; 32(9):528-534. PubMed ID: 26902255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of early adequate antimicrobial therapy on 14-day mortality in patients with monomicrobial Pseudomonas aeruginosa and Acinetobacter baumannii bacteremia.
    Park JH; Choi SH; Chung JW
    J Infect Chemother; 2013 Oct; 19(5):843-9. PubMed ID: 23665758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy.
    Choi IS; Lee YJ; Wi YM; Kwan BS; Jung KH; Hong WP; Kim JM
    Int J Antimicrob Agents; 2016 Aug; 48(2):175-80. PubMed ID: 27423416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Intravenous colistin in the treatment of infections due to pan-resistant Gram negative bacilli].
    Fica C A; Céspedes J I; Gompertz G M; Jalón V M; Sakurada Z A; Sáez L E
    Rev Chilena Infectol; 2007 Oct; 24(5):360-7. PubMed ID: 17989839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients.
    Kim WY; Moon JY; Huh JW; Choi SH; Lim CM; Koh Y; Chong YP; Hong SB
    PLoS One; 2016; 11(3):e0150642. PubMed ID: 26934182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of High Loading Dose of Colistin in Multidrug-Resistant
    Katip W; Meechoui M; Thawornwittayakom P; Chinwong D; Oberdorfer P
    J Intensive Care Med; 2019; 34(11-12):996-1002. PubMed ID: 28820037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii.
    Garnacho-Montero J; Amaya-Villar R; Gutiérrez-Pizarraya A; Espejo-Gutiérrez de Tena E; Artero-González ML; Corcia-Palomo Y; Bautista-Paloma J
    Chemotherapy; 2013; 59(3):225-31. PubMed ID: 24356297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
    Dickstein Y; Lellouche J; Ben Dalak Amar M; Schwartz D; Nutman A; Daitch V; Yahav D; Leibovici L; Skiada A; Antoniadou A; Daikos GL; Andini R; Zampino R; Durante-Mangoni E; Mouton JW; Friberg LE; Dishon Benattar Y; Bitterman R; Neuberger A; Carmeli Y; Paul M;
    Clin Infect Dis; 2019 Aug; 69(5):769-776. PubMed ID: 30462182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections.
    Bassetti M; Repetto E; Righi E; Boni S; Diverio M; Molinari MP; Mussap M; Artioli S; Ansaldi F; Durando P; Orengo G; Bobbio Pallavicini F; Viscoli C
    J Antimicrob Chemother; 2008 Feb; 61(2):417-20. PubMed ID: 18174197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extensively drug-resistant Acinetobacter baumannii bacteraemia in a multidisciplinary intensive care unit during a 6-year period: Risk factors for fulminant sepsis.
    Katsiari M; Mavroidi A; Platsouka ED; Nikolaou C
    J Glob Antimicrob Resist; 2018 Sep; 14():51-57. PubMed ID: 29471109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.
    Koomanachai P; Tiengrim S; Kiratisin P; Thamlikitkul V
    Int J Infect Dis; 2007 Sep; 11(5):402-6. PubMed ID: 17291803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of reduced tigecycline susceptibility on clinical outcomes of Acinetobacter bacteremia.
    Chang YY; Liu YM; Liu CP; Kuo SC; Chen TL;
    J Microbiol Immunol Infect; 2018 Feb; 51(1):148-152. PubMed ID: 29050749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical profile and outcomes of adult patients given intravenous colistin for multidrug-resistant gram negative infections in a Philippine tertiary hospital.
    Li KL; Abad CLR
    Int J Infect Dis; 2020 Apr; 93():9-14. PubMed ID: 31978579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors.
    Chiang MC; Kuo SC; Chen SJ; Yang SP; Lee YT; Chen TL; Fung CP
    Infection; 2012 Feb; 40(1):19-26. PubMed ID: 21887526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study.
    Raz-Pasteur A; Liron Y; Amir-Ronen R; Abdelgani S; Ohanyan A; Geffen Y; Paul M
    J Glob Antimicrob Resist; 2019 Jun; 17():168-172. PubMed ID: 30557685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report.
    Nakwan N; Wannaro J; Thongmak T; Pornladnum P; Saksawad R; Nakwan N; Chokephaibulkit K
    Pediatr Pulmonol; 2011 Jan; 46(1):60-6. PubMed ID: 20812247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of invasive Acinetobacter infection: A multicenter investigation with molecular identification of causative organisms.
    Kiyasu Y; Hitomi S; Funayama Y; Saito K; Ishikawa H
    J Infect Chemother; 2020 May; 26(5):475-482. PubMed ID: 31924521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.